The University of California, Los Angeles (UCLA) received a $128,509 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to develop a computational system called "TreatMonitor" for comprehensive cancer monitoring using multi-omics profiling of cell-free DNA (cfDNA). The key objectives of the project are to: 1) Improve monitoring of minimal residual disease (MRD) and cancer recurrence by integrating tumor signals from cfDNA exome and methylome data; and 2) Enable sensitive monitoring of treatment side effects by quantifying tissue contributions in cfDNA and identifying tissue damage. The project aims to achieve several milestones, including integrating cfDNA exome and methylome data for monitoring and developing the first cfDNA-based method for monitoring treatment side effects. The four-year grant period runs from April 1, 2025 to March 31, 2027 and supports UCLA's efforts to transition the project's principal investigator, Dr. Li, to an independent tenure-track faculty position in precision oncology.